BSEInsider Trading / SAST23 Jun 2026 · 23 Jun 2026, 12:09 pm
Closure of Trading Window
Shukra Pharmaceuticals Ltd · 524632
✦ AI Summary
Shukra Pharmaceuticals Ltd announced the closure of its trading window for designated persons, including promoters, directors, KMPs, and their immediate relatives. This measure, effective July 1, 2026, is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2026. This is a standard compliance procedure ahead of quarterly earnings announcements to prevent insider trading.
Analysis Scores
Earnings Impact5/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Shukra Pharmaceuticals Ltd - 524632 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
d16cb8ea-0472-4a69-9c7b-e5cb35dfc920.pdf
View document text
231 June, 2026
The General Manager-Listing
Corporate Relationship Department
The BSE Limited
Ground Floor, PJ Towers,
Dalal Street, Mumbai-400001
Security Code: 524632
Dear Sir/Madam,
Subject: Intimation for Closure of Trading Window for the Quarter Ended June 30, 2026
This is to inform you that the Company is closing its Trading window for dealing in the securities of
the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders,
Designated and Connected persons and their immediate relatives from Wednesday, July 1, 2026 till 48
hours after the declaration of its Unaudited Financial Results for the Quarter ended June 30, 2026
pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and
Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to
time) and SEBI Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and
SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 read with Company’s “Code of
Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by
Designated Persons" (“Insider Trading Code™).
Accordingly, all the Designated persons (including dependants and immediate relatives as per code)
and connected persons are advised not to enter into any transaction involving the securities of the
Company during the aforesaid period of closure of trading window.
The date of the Board Meeting in connection with publishing its Unaudited Financial Results for the
quarter ended June 30, 2026 will be announced in due course.
You are requested to take the same on record.
Thanking You.
Yours Faithfully,
For Shukra Pharmaceuticals Limited
Ritu Kapoo! I
Director
DIN: 10334249
CIN : L24231GJ1993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com